Sanofi
TrialSite News: Alzheimer’s Diagnostics Race Accelerates as Global Alzheimer’s Platform Expands Bio-Hermes-002 Study
TrialSite Staff | Making Biomedical Research Evidence Accessible to All May. 18, 2026, 2:30 p.m. The global battle against Alzheimer’s disease may increasingly hinge on one critical factor: detecting the disease earlier, faster, and more accurately before irreversible neurological decline takes hold. This week, the Global Alzheimer’s Platform Foundation (GAP) announced the continued expansion of its Bio-Hermes-002 […]
Noah News: Sanofi joins global coalition to enhance blood biomarkers for earlier Alzheimer’s detection
The Global Alzheimer’s Platform Foundation expands the Bio-Hermes-002 study, incorporating Sanofi and other industry leaders, to refine blood and digital biomarkers for more inclusive, earlier diagnosis of dementia… The Global Alzheimer’s Platform Foundation expands the Bio-Hermes-002 study, incorporating Sanofi and other industry leaders, to refine blood and digital biomarkers for more inclusive, earlier diagnosis of […]
Global Alzheimer’s Platform Foundation Announces Strategic Collaboration and Partnership for the Transformative Bio-Hermes-002 Study
Bio-Hermes-002 is a collaborative study focused on new biomarkers designed to improve diagnosis of Alzheimer’s disease and dementias. Washington D.C., May 18, 2026 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to announce the continued expansion of the Bio-Hermes-002 study, a unique observational platform study, which evaluates blood-based and digital biomarkers across a wide spectrum of cognitive conditions, alongside MRI and PET imaging and diverse […]